Billionaire Bruce Berkowitz Reveals 76% Of Fairholme Capital Is in Just 1 Stock
Bruce Berkowitz's Fairholme Capital disclosed in its Q2 2026 13F filing that 18,182,367 shares of St.
24/7 Wall Street8/18/2026Neutral
PFE
Pfizer IncNYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$153.15B
P/E Ratio
35.36
EPS
$0.76
Beta
0.28
52W High
$27.80
52W Low
$22.03
50-Day MA
$25.17
200-Day MA
$25.91
Dividend Yield
6.42%
Profit Margin
6.80%
Forward P/E
9.08
PEG Ratio
2.60
About Pfizer Inc
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Fundamentals
| Revenue (TTM) | $63.70B |
| Gross Profit (TTM) | $47.59B |
| EBITDA | $25.38B |
| Operating Margin | 27.90% |
| Return on Equity | 5.01% |
| Return on Assets | 5.78% |
| Revenue/Share (TTM) | $11.19 |
| Book Value | $14.95 |
| Price-to-Book | 1.79 |
| Price-to-Sales (TTM) | 2.40 |
| EV/Revenue | 3.206 |
| EV/EBITDA | 15.13 |
| Quarterly Earnings Growth (YoY) | -10.10% |
| Quarterly Revenue Growth (YoY) | 2.60% |
| Shares Outstanding | $5.70B |
| Float | $5.69B |
| % Insiders | 0.10% |
| % Institutions | 69.12% |
Historical Volatility
HV 10-Day
20.49%
HV 20-Day
17.62%
HV 30-Day
17.62%
HV 60-Day
20.75%
HV Rank
11.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($28.61 target)
2
Strong Buy8
Buy16
Hold1
Sell1
Strong SellLatest News
Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff
Pfizer remains a cautious Buy, trading near intrinsic value with an expected 10% annual return, primarily from its high dividend yield. PFE faces significant headwinds: a looming patent cliff, a stretched balance sheet, and questions about the sustainability of its dividend and growth prospects. Management projects high single-digit revenue CAGR post-2028, driven by acquisitions, pipeline progress, and aggressive cost-saving initiatives, though analysts remain skeptical.
Seeking Alpha8/18/2026Positive
Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase
Three Pfizer insiders executed transactions directly on the heels of the drugmaker's second-quarter earnings report.
Barrons8/14/2026Positive
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money
Pharmaceutical company Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. Approved by the FDA in May 2006 as a smoking-cessation aid, the drug was taken off the market in 2021.
Fast Company8/14/2026Negative
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.
GlobeNewsWire8/14/2026Neutral
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.
Zacks Investment Research8/12/2026Positive
Pfizer's Pipeline Could Change Everything
Pfizer is recovering from post-COVID and LOE-driven declines, with recent earnings beats and an attractive valuation supporting upside potential. PFE's Q2 2026 results showed 1% operational revenue growth and a 12% EPS beat, driven by solid non-COVID sales and a robust growth portfolio. Cost Realignment Program expansions are set to deliver $7.2B in net savings by 2026 and another $2.5B through 2029, enhancing future earnings.
Seeking Alpha8/11/2026Positive
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock
Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.
Zacks Investment Research8/10/2026Positive
Monster insider trading alert for Pfizer stock
As Pfizer Inc. (NYSE: PFE) stock gained over 5% this week fueled by its strong second quarter 2026 earnings report, Finbold has observed its increased insider trading.
Finbold8/7/2026Positive
After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.
24/7 Wall Street8/6/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PFE and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026